{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Wilmington",
      "state": "DE",
      "country": "United States",
      "classification": "Class I",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "90659",
      "recalling_firm": "Ultra Supplement LLC",
      "address_1": "1007 N Market St",
      "address_2": "N/A",
      "postal_code": "19801-1227",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.",
      "recall_number": "D-1350-2022",
      "product_description": "SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.",
      "product_quantity": "750 cartons",
      "reason_for_recall": "Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.",
      "recall_initiation_date": "20220721",
      "center_classification_date": "20220817",
      "termination_date": "20231016",
      "report_date": "20220810",
      "code_info": "Lot DAP272109, Exp: 4/1/2026"
    }
  ]
}